This panel considered the arguments for and against a system of differential pricing for combination therapies in Europe. They debated whether approaches to pricing in Europe are ready for new therapies coming to the market.

This webinar was commissioned and funded by Astellas Pharma Europe Ltd. The views expressed in this webinar are those of the speakers and do not necessarily represent the views of Astellas.